3-(6-Amino-pyridin-3-yl)-2-(1H-imidazol-4-yl)-propionic acid

ID: ALA302067

Chembl Id: CHEMBL302067

PubChem CID: 9837547

Max Phase: Preclinical

Molecular Formula: C11H12N4O2

Molecular Weight: 232.24

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ccc(CC(C(=O)O)c2c[nH]cn2)cn1

Standard InChI:  InChI=1S/C11H12N4O2/c12-10-2-1-7(4-14-10)3-8(11(16)17)9-5-13-6-15-9/h1-2,4-6,8H,3H2,(H2,12,14)(H,13,15)(H,16,17)

Standard InChI Key:  IFHWJTOFROTZBD-UHFFFAOYSA-N

Associated Targets(Human)

CPB2 Tchem Carboxypeptidase B2 isoform A (351 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CPA1 Tchem Carboxypeptidase A1 (146 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CPM Tchem Carboxypeptidase M (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CPB1 Tchem Carboxypeptidase B (100 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 232.24Molecular Weight (Monoisotopic): 232.0960AlogP: 0.80#Rotatable Bonds: 4
Polar Surface Area: 104.89Molecular Species: ACIDHBA: 4HBD: 3
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 3.52CX Basic pKa: 7.67CX LogP: -1.29CX LogD: -1.33
Aromatic Rings: 2Heavy Atoms: 17QED Weighted: 0.72Np Likeness Score: 0.40

References

1. Nantermet PG, Barrow JC, Lindsley SR, Young M, Mao SS, Carroll S, Bailey C, Bosserman M, Colussi D, McMasters DR, Vacca JP, Selnick HG..  (2004)  Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group.,  14  (9): [PMID:15080996] [10.1016/j.bmcl.2004.02.033]
2. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]
3. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]
4. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C, Cook JJ, Sitko G, Tiller PR, Miller-Stein CM, Rose M, McMasters DR, Vacca JP, Selnick HG..  (2003)  Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.,  46  (25): [PMID:14640538] [10.1021/jm034141y]
5. Brink M, Dahlén A, Olsson T, Polla M, Svensson T..  (2014)  Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).,  22  (7): [PMID:24588961] [10.1016/j.bmc.2014.02.010]

Source